3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Urologic Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Laryngeal Diseases
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
temsirolimus
1
pembrolizumab
1
niraparib
1
atezolizumab
1
Valproic Acid
1
Tissue Banks
1
Sirolimus
1
Immunoglobulin G
1
GSK-3326595
1
Etoposide
1
Disulfides
1
Cyclophosphamide
1
Cetuximab
1
Blood Specimen Collection
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
niraparib
×
Head & Neck
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts